The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1287
June 2, 2008
View Complete Issue         Table of Contents 2019 
Bevacizumab (Avastin) for Metastatic Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bevacizumab (Avastin) for Metastatic Breast Cancer
June 2, 2008 (Issue: 1287)
Bevacizumab (Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting formation of new blood vessels. Previously...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bevacizumab (Avastin) for Metastatic Breast Cancer
Article code: 1287b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.